Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 523

1.

Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes.

Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, Lang R, Mages J, Kempkes B.

PLoS Pathog. 2009 Jul;5(7):e1000506. doi: 10.1371/journal.ppat.1000506. Epub 2009 Jul 3.

3.

Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins.

Young LS, Finerty S, Brooks L, Scullion F, Rickinson AB, Morgan AJ.

J Virol. 1989 May;63(5):1967-74.

4.

Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.

Rasul AE, Nagy N, Sohlberg E, Ádori M, Claesson HE, Klein G, Klein E.

J Immunol Methods. 2012 Nov 30;385(1-2):60-70. doi: 10.1016/j.jim.2012.08.008. Epub 2012 Aug 18.

PMID:
22921685
5.

Epstein-Barr Virus EBNA-2 gene expression enhances lymphotoxin production by B lymphocytes.

McClain K, Estrov Z, Raju U, Kelley PK, Aggarwal BB.

Methods. 1997 Jan;11(1):83-7.

PMID:
8990093
6.

Immortalizing genes of Epstein-Barr virus.

Middleton T, Gahn TA, Martin JM, Sugden B.

Adv Virus Res. 1991;40:19-55. Review.

PMID:
1659776
7.

[Studies on transforming functions of Epstein-Barr virus-specific proteins].

Kinoshita T.

Hokkaido Igaku Zasshi. 1990 Jul;65(4):362-75. Japanese.

PMID:
2172130
8.
9.

Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.

Hu LF, Chen F, Altiok E, Winberg G, Klein G, Ernberg I.

Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:248-60.

PMID:
10895161
10.

Early events in Epstein-Barr virus infection of human B lymphocytes.

Alfieri C, Birkenbach M, Kieff E.

Virology. 1991 Apr;181(2):595-608. Erratum in: Virology 1991 Dec;185(2):946.

PMID:
1849678
11.

Nuclear receptors and their role in Epstein -- Barr virus induced B cell transformation.

Yenamandra SP, Klein G, Kashuba E.

Exp Oncol. 2009 Jun;31(2):67-73. Review.

PMID:
19550394
12.
14.

Cellular target genes of Epstein-Barr virus nuclear antigen 2.

Maier S, Staffler G, Hartmann A, Höck J, Henning K, Grabusic K, Mailhammer R, Hoffmann R, Wilmanns M, Lang R, Mages J, Kempkes B.

J Virol. 2006 Oct;80(19):9761-71.

15.
16.

Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.

Niller HH, Wolf H, Minarovits J.

Autoimmunity. 2008 May;41(4):298-328. doi: 10.1080/08916930802024772. Review.

PMID:
18432410
17.

C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.

Cancian L, Bosshard R, Lucchesi W, Karstegl CE, Farrell PJ.

PLoS Pathog. 2011 Jul;7(7):e1002164. doi: 10.1371/journal.ppat.1002164. Epub 2011 Jul 28.

18.

Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.

Kalla M, Hammerschmidt W.

Eur J Cell Biol. 2012 Jan;91(1):65-9. doi: 10.1016/j.ejcb.2011.01.014. Epub 2011 Mar 29. Review.

PMID:
21450364
20.

Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.

Seo JS, Cho NY, Kim HR, Tsurumi T, Jang YS, Lee WK, Lee SK.

Oncol Rep. 2008 Jan;19(1):93-8.

PMID:
18097580

Supplemental Content

Support Center